Xarelto 20 mg film-coated tablets
Sponsors
Royal College Of Surgeons In Ireland, Royal College Of Surgeons In Ireland, Stichting Radboud University Medical Center, Amsterdam UMC, Anthos Therapeutics Inc., Sint Antonius Ziekenhuis Stichting
Conditions
Acute Venous ThromboembolismAtrial FibrillationAtrial fibrillationCoronary artery diseaseHealthy subjectsPatent foramen ovale or atrial septum defectPercutaneous coronary interventionshort bowel syndrome
Phase 2
A Multicenter, RandomiZed, Active-ControLled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab (MAA868) Compared with Open-Label Rivaroxaban in Patients with Atrial Fibrillation (AZALEA)
Active, not recruitingCTIS2023-509066-38-00
Start: 2021-04-16Target: 896Updated: 2025-10-15
Platelet inhibition versus direct oral anticoagulation in patients undergoing percutaneous closure of patent foramen ovale or atrial septal defect
RecruitingCTIS2024-517115-70-00
Start: 2022-05-04Target: 52Updated: 2024-08-15
Phase 4
COmparison of Bleeding Risk between Rivaroxaban and
Apixaban for the treatment of acute venous thromboembolism
CompletedCTIS2023-504179-26-00
Start: 2024-07-19End: 2025-04-10Target: 24Updated: 2024-07-15
Rivaroxaban sotorasib interaction study (the ROSIE-study)
CompletedCTIS2023-505557-41-00
Start: 2023-11-09End: 2024-03-21Target: 22Updated: 2023-08-01
Rivaroxaban Monotherapy and CYP2C19 Genotype Testing in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention
RecruitingCTIS2023-508904-39-00
Start: 2024-08-22Target: 50Updated: 2024-06-21
EvaluaTion of Clinical and laboratory outcomes of Rivaroxaban in short Bowel syndrome patients dEpending on Long term parenteral nutrition: a prospective cohort study (TINCRBEL study)
Not yet recruitingCTIS2024-519078-38-00
Target: 24Updated: 2024-11-22